Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 12/20 | 0.40 |
| ▸ | BCHE | P06276 | 3/20 | 0.37 |
| ▸ | KLK7 | P49862 | 3/20 | 0.36 |
| ▸ | KLK5 | Q9Y337 | 3/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30765608 | 0.93 | GAA (0.41) | GAAL3MBTL1ELANEBCHEADORA3 | |
| SCHEMBL30766052 | 0.90 | KLK7 (0.42) | ELANEBCHEKLK7KLK5 | |
| SCHEMBL30765613 | 0.84 | GAA (0.50) | GAAL3MBTL1ELANE | |
| SCHEMBL30765978 | 0.84 | ELANE (0.41) | ELANEBCHEADORA3ADORA2B | |
| SCHEMBL30765463 | 0.83 | GAA (0.44) | GAAL3MBTL1ELANEADORA3ADORA2B | |
| SCHEMBL30765476 | 0.83 | ELANE (0.40) | ELANEBCHEKLK7KLK5 | |
| SCHEMBL30765664 | 0.83 | BCHE (0.44) | ELANEBCHEKLK7KLK5 | |
| SCHEMBL30765744 | 0.82 | BCHE (0.38) | GAAL3MBTL1BCHE | |
| SCHEMBL30765687 | 0.82 | BCHE (0.41) | ELANEBCHEADORA3ADORA2B | |
| SCHEMBL30766150 | 0.80 | GAA (0.52) | GAAL3MBTL1ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4568666-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Alexion Pharmaceuticals, Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| WO-2024035686-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2024-02-15 | — | — | WO | disclosed |